Skip to main content

Table 3 Comparison of demographic and clinical parameters between increased and non-increased BMD groups a

From: Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Parameters

Lumbar spine BMD

p-value c

Femoral neck BMD

p-value c

Increased group (≥ 3% per year) n = 17 b

Non-increased group (< 3% per year) n = 11 b

Increased group (≥ 3% per year) n = 6 b

Non-increased group (< 3% per year) n = 22 b

Age (years), median (IQR)

37.0 (34.5–40.5)

43.0 (39.0–46.0)

0.018

40.5 (32.3–45.0)

39.0 (35.0–43.3)

0.978

Gender, male, n (%)

15 (88.2)

10 (90.9)

1.000

6 (100)

19 (86.4)

1.000

Body mass index (kg/m2), median (IQR)

20.2 (18.9–23.8)

19.8 (17.9–23.7)

0.452

23.2 (18.4–23.7)

20.0 (18.6–23.8)

0.675

Current smoking, n (%)

9 (52.9)

2 (18.2)

0.115

1 (16.7)

10 (45.5)

0.355

Prior AIDS diagnosis, n (%)

4 (23.5)

5 (45.5)

0.409

2 (33.3)

7 (31.8)

1.000

Time since diagnosis HIV (years), median (IQR)

1 (1–6.5)

4 (1–12)

0.325

1 (0.75–6.8)

4 (1–9)

0.458

CD4 cell count, median (IQR)

394 (301–545)

766 (149–907)

0.132

518 (180–782)

436 (306–804)

0.716

Time on antiretroviral therapy (years), median (IQR)

2 (1–5)

4 (1–9)

0.258

2 (1–5)

4 (1–8)

0.492

TFV use at baseline, n (%)

16 (94.1)

6 (54.5)

0.022

5 (83.3)

17 (77.3)

1.000

BP pre-treatment, n (%)

1 (5.9)

4 (36.4)

0.062

0 (0)

5 (22.7)

0.553

Lumbar spine BMD at baseline (g/cm2), median (IQR)

0.789 (0.723–0.845)

0.867 (0.774–0.912)

0.105

0.827 (0.769–0.883)

0.800 (0.732–0.874)

0.801

Femoral neck BMD at baseline (g/cm2), median (IQR)

0.606 (0.574–0.679)

0.623 (0.540–0.654)

0.621

0.602 (0.568–0.655)

0.615 (0.568–0.680)

0.654

Denosumab treatment initiated before the COVID-19 pandemic, n (%)

13 (76.5)

8 (72.7)

1.000

5 (83.3)

16 (72.7)

1.000

Adherence at 12 months, n (%)

14 (82.4)

11 (100)

0.258

6 (100)

19 (86.4)

1.000

Adherence at 24 months, n (%)

12 (70.6)

6 (54.5)

0.444

5 (83.3)

13 (59.1)

0.375

MCR to follow-up (%), median (IQR)

95.0 (92.3–98.9)

98.6 (93.2–99.1)

0.525

95.6 (91.6–99.3)

95.2 (92.4–99.1)

0.889

  1. Abbreviations: AIDS acquired immunodeficiency syndrome, BMD bone mineral density, BMI body mass index, BP bisphosphonate, COVID coronavirus disease, HIV human immunodeficiency virus, IQR interquartile range, MCR medication coverage ratio, TFV tenofovir
  2. a Data are expressed as numbers and frequencies (%) or median values with IQR
  3. b Patients who did not undergo follow-up BMD measurements were excluded from the analysis
  4. c Fisher’s exact test was used for categorical data, and the Mann–Whitney U test was used for continuous data
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us